| Literature DB >> 27879334 |
Youngbeom Ahn1, Jeong Myeong Kim1, Ohgew Kweon1, Seong-Jae Kim1, Richard C Jones2, Kellie Woodling3, Gonçalo Gamboa da Costa3, John J LiPuma4, David Hussong5, Bernard S Marasa6, Carl E Cerniglia7.
Abstract
Pharmaceutical products that are contaminated with Burkholderia cepacia complex (BCC)Entities:
Mesh:
Substances:
Year: 2016 PMID: 27879334 PMCID: PMC5120141 DOI: 10.1128/mBio.01716-16
Source DB: PubMed Journal: mBio Impact factor: 7.867
Susceptibility of BCC strains to BZK, C14BDMA-Cl, C12BDMA-Cl, C10BDMA-Cl, C6BDMA-Cl, and BTMA-Cl after 7 days
| No | Strain | MICs (μg/ml) on 1/10-diluted TSB | |||||
|---|---|---|---|---|---|---|---|
| BZK | C14BDMA-Cl | C12BDMA-Cl | C10BDMA-Cl | C6BDMA-Cl | BTMA-Cl | ||
| 1 | 128 | 128 | 128 | 1,024 | >1,024 | >1,024 | |
| 2 | 256 | 128 | 128 | 1,024 | >1,024 | >1,024 | |
| 3 | 128 | 128 | 128 | 1,024 | >1,024 | >1,024 | |
| 4 | 128 | 128 | 128 | 1,024 | >1,024 | >1,024 | |
| 5 | 128 (256) | 128 | 128 | 1,024 | >1,024 | >1,024 | |
| 6 | 64 (128) | 64 (128) | 64 (128) | 128 (512) | >1,024 | >1,024 | |
| 7 | 128 | 128 | 128 | 512 (1,024) | >1,024 | >1,024 | |
| 8 | 128 | 128 | 128 | 512 (1,024) | >1,024 | >1,024 | |
| 9 | 128 | 128 | 128 | 1,024 | >1,024 | >1,024 | |
| 10 | 128 | 128 | 64 (128) | 512 (1,024) | >1,024 | >1,024 | |
| 11 | 128 | 128 | 64 (128) | 512 (1,024) | >1,024 | >1,024 | |
| 12 | 128 | 128 | 128 | 1,024 | >1,024 | >1,024 | |
| 13 | 256 | 128 | 128 | 1,024 | >1,024 | >1,024 | |
| 14 | 128 | 128 | 128 | 1,024 | >1,024 | >1,024 | |
| 15 | 256 | 128 | 256 | 1,024 | >1,024 | >1,024 | |
| 16 | 128 | 128 | 128 | 1,024 | >1,024 | >1,024 | |
| 17 | 128 | 128 | 256 | 1,024 | >1,024 | >1,024 | |
| 18 | 256 | 256 | 256 | 1,024 | >1,024 | >1,024 | |
| 19 | 256 | 256 | 256 | 1,024 | >1,024 | >1,024 | |
| 20 | 128 | 256 | 256 | 1,024 | >1,024 | >1,024 | |
Minimum recovery concentration on 1/10-diluted TSB.
FIG 1 Effects of the efflux pump inhibitor CCCP on the growth of B. cenocepacia AU1054 in 1/10-diluted TSB medium containing 60 µg/ml C12BDMA-Cl.
Degradation of BZK, C12BDMA-Cl and C10BDMA-Cl by BCC strains
| No. | Strain | Concentration in µg/ml (mean % ± SD) | |||
|---|---|---|---|---|---|
| BZK | C12BDMA-Cl | C10BDMA-Cl | |||
| 1 | 64 | 64 (18.0 ± 1.8) | 128 (18.4 ± 0.3) | ||
| 2 | 64 (24.0 ± 4.7) | 64 (8.6 ± 0.9) | 128 (24.0 ± 4.7) | ||
| 3 | 64 (21.7 ± 1.2) | 64 (8.2 ± 2.6) | 128 (21.7 ± 1.2) | ||
| 4 | 64 (25.3 ± 2.4) | 64 (6.6 ± 3.6) | 128 (25.3 ± 2.4) | ||
| 5 | 64 (22.4 ± 1.5) | 64 (9.9 ± 1.1) | 128 (22.4 ± 1.5) | ||
| 6 | 32 (12.6 ± 1.9) | 32 (6.4 ± 2.9) | 128 (12.6 ± 1.9) | ||
| 7 | 64 (22.9 ± 7.7) | 64 (8.6 ± 2.2) | 128 (22.9 ± 7.7) | ||
| 8 | 64 (19.6 ± 4.4) | 64 (6.1 ± 0.8) | 128 (19.6 ± 4.4) | ||
| 9 | 64 (42.6 ± 12.3) | 64 (66.1 ± 0.6) | 128 (42.6 ± 1.3) | ||
| 10 | 64 (21.9 ± 0.4) | 32 (8.5 ± 2.4) | 128 (2.9 ± 0.4) | ||
| 11 | 64 (7.5 ± 5.8) | 32 (3.2 ± 0.3) | 128 (7.5 ± 5.8) | ||
| 12 | 64 (14.6 ± 3.8) | 64 (4.3 ± 0.3) | 128 (14.6 ± 3.8) | ||
| 13 | 64 (12.3 ± 2.8) | 64 (8.1 ± 4.2) | 128 (14.9 ± 0.9) | ||
| 14 | 64 (9.6 ± 4.3) | 64 (7.9 ± 2.9) | 128 (9.6 ± 4.3) | ||
| 15 | 64 (11.1 ± 3.1) | 64 (6.4 ± 2.5) | 128 (11.1 ± 3.1) | ||
| 16 | 64 (4.7 ± 2.4) | 64 (5.6 ± 0.6) | 128 (4.7 ± 2.4) | ||
| 17 | 64 (6.7 ± 3.4) | 64 (3.7 ± 1.5) | 128 (6.7 ± 3.4) | ||
| 18 | 64 (13.5 ± 6.7) | 64 (5.9 ± 2.3) | 128 (13.5 ± 6.7) | ||
| 19 | 64 (10.4 ± 10.7) | 64 (8.3 ± 2.3) | 128 (10.4 ± 1.7) | ||
| 20 | 64 (21.9 ± 1.7) | 64 (4.5 ± 0.7) | 128 (21.9 ± 1.7) | ||
Applied concentration of BZK and alkyl derivatives for degradation.
Percent degradation of BZK and alkyl derivatives after 7 days of incubation.
FIG 2 LC-MS analysis evidencing the degradation of C12BDMA-Cl to BDMA and BMA by B. cenocepacia AU1054. (A) BDMA and BMA at a standard (std) concentration of 100 ng/ml. BDMA elutes at ~1.0 min, whereas BMA elutes at ~2.0 min. Only the primary transitions are shown. However, the secondary transitions were acquired and seen for each compound. (B) Control sample without the addition of C12BDMA-Cl after 7 days of incubation. (C) Terminal-point sample taken after 7 days of incubation with the addition of C12BDMA-Cl.
FIG 3 Summary of proteins identified in this proteome study. (A) Time course of sampling. (B) Cluster analysis of proteomic data sets showing the correlation between protein expression profiles and treatment time. (C) Venn diagram analysis of the proteome (3,747/6,632).
FIG 4 Protein expression pattern analysis by STEM (42) and functional distribution of the up- or downregulated proteins. ISP, information storage and processing; CPS, cellular processes and signaling; Met, metabolism; PC, poorly characterized. COG functional categories: D, cell cycle control, cell division, chromosome partitioning; M, cell wall/membrane/envelope biogenesis; N, cell motility; O, posttranslational modification, protein turnover, and chaperones; T, signal transduction mechanisms; U, intracellular trafficking, secretion, and vesicular transport; V, defense mechanisms; J, translation, ribosomal structure, and biogenesis; K, transcription; L, replication, recombination, and repair; C, energy production and conversion; E, amino acid transport and metabolism; F, nucleotide transport and metabolism; G, carbohydrate transport and metabolism; H, coenzyme transport and metabolism; I, lipid transport and metabolism; P, inorganic ion transport and metabolism; Q, secondary metabolite biosynthesis, transport, and catabolism; R, general function prediction only; S, function unknown.
FIG 5 Transporter expression pattern analysis by STEM and transporter information belonging to STEM patterns 5, 7, and 8. TransportDB (65) was used for annotation and classification of transport genes from B. cenocepacia AU1054. D0, time zero; D3, day 3; D7, day 7.
FIG 6 The intrinsic resistance mechanisms of efflux pumps and biodegradation of BZK in BCC strains. The aromatic and alkane groups of BZK are highlighted with green and blue ellipses, respectively. In the BZK degradation pathway, solid arrows indicate one-step reactions, while dashed arrows indicate multiple steps of enzyme reactions. TCA, tricarboxylic acid.